Top Page
Living Cell Technologies
(Sydney:1AI)
Living Cell Technologies (1AI) vs. iShares MSCI Australia ETF (EWA)
Living Cell Technologies Business Overview & Revenue Model
Living Cell Technologies Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2024 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -557.00 | -743.00 | -49.31K |
| EBITDA | -2.04M | -1.54M | -2.10M | -2.13M | -2.38M | -1.86M |
| Net Income | -1.01M | -802.96K | -2.10M | -2.11M | -1.96M | -1.46M |
Balance Sheet | ||||||
| Total Assets | 2.00M | 2.40M | 5.49M | 6.23M | 4.27M | 1.64M |
| Cash, Cash Equivalents and Short-Term Investments | 1.88M | 2.32M | 3.11M | 6.13M | 7.24M | 1.61M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 111.25K | 169.76K | 178.45K | 449.86K | 239.26K | 265.08K |
| Stockholders Equity | 1.89M | 2.23M | 3.01M | 3.76M | 4.03M | 1.38M |
Cash Flow | ||||||
| Free Cash Flow | -702.90K | -785.25K | -1.52M | -1.99M | -2.05M | -1.46M |
| Operating Cash Flow | -702.90K | -785.25K | -1.52M | -1.99M | -2.04M | -1.46M |
| Investing Cash Flow | 1.35M | 450.00K | -277.44K | 0.00 | 39.50K | 105.86K |
| Financing Cash Flow | 179.59K | -3.00K | 523.00K | 1.85M | 4.69M | -44.54K |
Living Cell Technologies Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$8.27M | -3.15 | -8.72% | ― | ― | 71.10% | |
48 Neutral | AU$10.68M | -1.00 | -166.70% | ― | ― | ― | |
45 Neutral | AU$8.84M | -0.15 | 2844.96% | ― | ― | 46.28% | |
42 Neutral | AU$23.98M | -6.84 | -49.25% | ― | ― | ― | |
40 Underperform | AU$33.26M | -5.38 | -16.65% | ― | ― | -672.73% | |
39 Underperform | AU$17.08M | -1.59 | -90.15% | ― | -93.83% | 20.00% |
Living Cell Technologies Corporate Events
Algorae Pharmaceuticals has issued 42,000,000 unquoted performance rights under its employee incentive scheme, effective 5 March 2026. The large grant of performance rights underscores the company’s reliance on equity-based remuneration to incentivise staff, potentially increasing future share dilution while aiming to strengthen retention and align employees with strategic and financial goals.
The issue of these unquoted securities indicates an effort to motivate key contributors without immediate cash outlay, a common practice among growth-oriented pharmaceutical firms. For existing shareholders, the move signals an emphasis on long-term value creation tied to performance milestones, but also highlights the need to monitor the impact of future vesting on the company’s capital structure.
The most recent analyst rating on (AU:1AI) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
Algorae Pharmaceuticals has disclosed a change in director David Hainsworth’s interests following the exercise of options through his controlled entity Union Square Capital Pty Ltd. The transaction saw the conversion of 312,500 options into ordinary shares and the disposal of an equivalent number of 1AIO options, modestly increasing his indirect shareholding while simplifying his mix of derivative securities.
After the change, Hainsworth’s indirect holding rose to 5,937,500 ordinary shares, alongside existing unlisted options, while his substantial direct holdings of shares, performance rights and options remained unchanged. The move signals continued equity alignment between the director and shareholders, but does not alter the company’s broader capital structure or indicate any change in strategic direction.
The most recent analyst rating on (AU:1AI) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
Algorae Pharmaceuticals has issued new fully paid ordinary shares, as detailed in an Appendix 2A lodged with the ASX, and has done so without a prospectus under the disclosure exemptions of the Corporations Act. The company confirms it is up to date with its financial reporting and continuous disclosure obligations, and that there is no excluded information that must be revealed, effectively clearing the way for the newly issued shares to be freely traded and providing assurance to investors about regulatory compliance.
The most recent analyst rating on (AU:1AI) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
Algorae Pharmaceuticals Limited has applied to the ASX for quotation of 5,062,500 new ordinary fully paid shares under the code 1AI, with an issue date of March 5, 2026. The additional quoted securities, arising from the exercise or conversion of existing instruments, expand the company’s listed share base and may enhance liquidity for investors while modestly diluting existing shareholders’ holdings.
The move signals ongoing capital structuring activity as Algorae Pharmaceuticals advances its operations and funding plans within the biotech sector. By increasing the number of quoted securities, the company is positioning itself to support future development initiatives and maintain its presence in the public capital markets.
The most recent analyst rating on (AU:1AI) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
Algorae Pharmaceuticals has issued new fully paid ordinary shares, as detailed in a contemporaneous Appendix 2A lodgement, and has confirmed that these securities were issued without a prospectus under the Act’s disclosure exemptions. The company states it remains compliant with its financial reporting and continuous disclosure obligations and that no excluded information is required to be disclosed, indicating the new share issue is procedurally routine and not driven by undisclosed material developments.
This cleansing notice assures investors that Algorae has met all relevant Corporations Act requirements in connection with the latest share issuance. By confirming there is no additional undisclosed price-sensitive information, the company seeks to maintain transparency and regulatory confidence around its capital management activities while potentially broadening its shareholder base.
The most recent analyst rating on (AU:1AI) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
Algorae Pharmaceuticals Limited has applied to the Australian Securities Exchange for quotation of 7,377,816 new ordinary fully paid shares under its existing ticker 1AI. The new securities, issued on February 27, 2026, arise from the exercise or conversion of previously outstanding options or other convertible instruments, modestly expanding the company’s free float and potentially increasing liquidity for shareholders.
The application formalizes the admission of these additional shares to trading on the ASX and reflects ongoing capital structuring activity within the company. While no specific use of proceeds is disclosed in the filing, the enlarged quoted capital base may provide Algorae Pharmaceuticals with greater financial flexibility and a broader shareholder base as it pursues its pharmaceutical development objectives.
The most recent analyst rating on (AU:1AI) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
Algorae Pharmaceuticals has released its half-year report for the six months ended 31 December 2025, providing the market with an update on its activities and financial performance over the period. The announcement, approved by the board, underscores the company’s dual-track strategy of advancing AI-driven drug discovery alongside expanding its commercial medicines business in Australia and New Zealand.
By highlighting both its proprietary AlgoraeOS platform and the AlgoraeRx commercialisation arm, the update reinforces Algorae’s positioning at the intersection of AI technology and traditional pharmaceuticals. This integrated model is intended to support the translation of AI-predicted therapies into practice while broadening patient access to high-quality medicines through research collaborations and established distribution channels.
The most recent analyst rating on (AU:1AI) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
Algorae Pharmaceuticals has signed a definitive licence and supply agreement with India’s Cadila Pharmaceuticals to launch two generic medicines for cardiovascular and metabolic disorders in Australia and New Zealand. Under the deal, Cadila will handle development and manufacturing, while Algorae, via its AlgoraeRx unit, will act as TGA sponsor and lead regulatory and commercial efforts across the region.
The Cadila tie-up builds on Algorae’s existing oncology-focused licensing arrangement with Sakar Healthcare for five generic cancer drugs and its recent distribution deal with Dr. Reddy’s for Capecitabine 500 mg in Australia. Together, these partnerships are building a multi-partner, multi-therapy platform that broadens Algorae’s product base across oncology, cardiovascular and metabolic diseases, strengthening its presence with hospitals, pharmacies and institutional buyers in Australia and New Zealand.
The most recent analyst rating on (AU:1AI) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
Algorae Pharmaceuticals has released a February 2026 non-deal investor presentation outlining general information about the company and its activities, while emphasising that the document is for informational purposes only and does not constitute an offer or solicitation to buy or sell securities. The presentation is framed by extensive disclaimers highlighting the speculative nature of any investment in the company, the confidentiality of the material, the absence of financial product advice, and the inherent risks and uncertainties associated with any statements about future intentions or performance, signalling a cautious approach to investor communications and risk management.
The most recent analyst rating on (AU:1AI) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
Algorae Pharmaceuticals Limited has applied to the ASX for quotation of 47,745 new fully paid ordinary shares under its ticker 1AI, issued on 2 February 2026 following the exercise of options or conversion of other securities. The modest increase in quoted securities slightly expands the company’s free float and capital base, signalling ongoing use of equity-linked instruments in its funding structure but without indicating any immediate transformational change to its operations or market position.
The most recent analyst rating on (AU:1AI) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
Algorae Pharmaceuticals reported strong progress for the December 2025 quarter, highlighted by a new distribution agreement with Dr. Reddy’s Laboratories for Capecitabine 500mg tablets that marks a key step toward oncology revenue in Australia and New Zealand and is backed by a new $3 million debt facility with ScotPac to fund inventory and supply opportunities. On the R&D front, the company launched AlgoraeOS v2, a significantly upgraded AI drug discovery platform that has outperformed leading benchmark models and generated more than 500,000 in silico CBD–drug–cell line predictions, with independent validation of the earlier version at the Peter MacCallum Cancer Centre confirming its predictive power and yielding 90 high-priority combination candidates for further development, supported by a cash inflow from the R&D tax incentive and the forthcoming arrival of a seasoned chief operating officer to scale commercial operations.
The most recent analyst rating on (AU:1AI) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
Algorae Pharmaceuticals has secured a A$3.0 million receivables-based working capital facility from ScotPac Business Finance for an initial 24-month term, providing a revolving, non-dilutive source of funding that can be drawn and repaid flexibly with interest charged only on utilised amounts. The facility, secured against AlgoraeRx’s trade receivables and backed by a parent guarantee, is intended to bolster the company’s working capital, enabling faster inventory deployment and execution of supply opportunities, thereby supporting the scaling of its revenue-generating commercialisation operations across Australia and New Zealand and strengthening its financial flexibility without issuing new equity.
The most recent analyst rating on (AU:1AI) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
Algorae Pharmaceuticals has disclosed a change in director David Hainsworth’s interests in the company’s securities following his participation in a loyalty option offer. Hainsworth, who holds both direct and indirect stakes, acquired a total of 5,125,000 new unlisted options exercisable at $0.014 and expiring on 1 December 2029, at an issue price of $0.001 per option, increasing his exposure to the company’s equity without disposing of any existing securities, which further aligns his incentives with long‑term shareholder value.
Algorae Pharmaceuticals Limited has notified the market of the issue of 199,013,513 unquoted options, each expiring on 1 December 2029, under the ASX code 1AIAT. The options, which are not intended to be quoted on the ASX, were issued as part of previously announced transactions, signalling a significant expansion of the company’s unquoted equity base and potentially affecting capital structure and future shareholder dilution dynamics.
Algorae Pharmaceuticals Limited has applied for quotation of 1,663 new fully paid ordinary shares on the ASX, with an issue date of 19 December 2025. The small-scale share issuance, arising from the exercise or conversion of existing instruments, marginally increases the company’s quoted capital and reflects ongoing capital management activities without significantly altering its overall market position or capital structure.
Algorae Pharmaceuticals has closed its non-renounceable pro-rata loyalty options entitlement offer, receiving applications for 199,013,513 options at $0.001 each and raising approximately $199,014 before costs, with the options expected to be issued on 22 December 2025. The remaining 138,737,943 options constitute a shortfall that will be placed at the company’s discretion under a separate shortfall offer within three months, with funds from both offers earmarked for offer costs and general working capital, modestly strengthening Algorae’s balance sheet and providing incremental support for its AI-driven drug discovery and commercialisation activities.
Algorae Pharmaceuticals has announced the receipt of comprehensive in silico synergy predictions from its AI platform, AlgoraeOS v2, which evaluates over 500,000 CBD-drug-cell line combinations. The platform outperforms existing models, including those from Google DeepMind, across major synergy metrics, and has identified 90 high-quality drug combination candidates for further evaluation. The company is in discussions with the Peter MacCallum Cancer Centre for independent validation of these results, marking a significant step in its AI-driven drug discovery efforts.
Algorae Pharmaceuticals has received a cash refund of $384,466.78 from the Australian Taxation Office under the R&D Tax Incentive program for its eligible research and development activities in 2025. This non-dilutive funding will bolster the company’s financial position and support its AI-driven drug discovery programs and commercial pipeline, reflecting its commitment to innovative pharmaceutical development.